News
Themis: Chikungunya vaccine development towards Phase III trials receives £ 3 Mio. boost by Innovate UK
- Details

Immatics initiates personalized adoptive cellular therapy in patients with relapsed and/or refractory solid cancers using its pioneering target warehouse
- Details
